Sivik Global Healthcare LLC Makes New $4.71 Million Investment in DaVita Inc. (NYSE:DVA)

Sivik Global Healthcare LLC purchased a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 45,000 shares of the company's stock, valued at approximately $4,714,000.

Other institutional investors have also added to or reduced their stakes in the company. Hanseatic Management Services Inc. purchased a new position in shares of DaVita during the 3rd quarter valued at about $36,000. GAMMA Investing LLC bought a new position in shares of DaVita during the 4th quarter valued at $60,000. FinTrust Capital Advisors LLC grew its stake in shares of DaVita by 242.3% during the third quarter. FinTrust Capital Advisors LLC now owns 712 shares of the company's stock valued at $67,000 after buying an additional 504 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of DaVita by 1,284.4% in the third quarter. Federated Hermes Inc. now owns 1,246 shares of the company's stock worth $118,000 after buying an additional 1,156 shares during the period. Finally, Tacita Capital Inc purchased a new stake in DaVita during the 3rd quarter valued at about $118,000. 90.12% of the stock is owned by institutional investors.

Insider Activity

In other DaVita news, COO Michael David Staffieri sold 29,488 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $119.81, for a total value of $3,532,957.28. Following the transaction, the chief operating officer now directly owns 37,687 shares in the company, valued at $4,515,279.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, COO Michael David Staffieri sold 29,488 shares of the firm's stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $119.81, for a total value of $3,532,957.28. Following the transaction, the chief operating officer now owns 37,687 shares of the company's stock, valued at $4,515,279.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider James O. Hearty sold 26,164 shares of the business's stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total value of $3,130,260.96. Following the transaction, the insider now owns 20,264 shares of the company's stock, valued at $2,424,384.96. The disclosure for this sale can be found here. Insiders sold 134,540 shares of company stock valued at $16,551,071 in the last quarter. 1.40% of the stock is currently owned by insiders.

DaVita Stock Up 0.6 %

NYSE:DVA traded up $0.87 on Tuesday, reaching $139.01. 946,961 shares of the stock traded hands, compared to its average volume of 802,684. The company has a current ratio of 1.19, a quick ratio of 1.13 and a debt-to-equity ratio of 6.65. The company has a market capitalization of $12.19 billion, a price-to-earnings ratio of 18.79, a PEG ratio of 1.19 and a beta of 1.04. DaVita Inc. has a 12 month low of $71.51 and a 12 month high of $141.54. The company's fifty day simple moving average is $132.44 and its 200 day simple moving average is $111.30.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, February 13th. The company reported $1.87 EPS for the quarter, topping analysts' consensus estimates of $1.53 by $0.34. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The business had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.01 billion. During the same quarter last year, the company earned $1.11 EPS. The company's quarterly revenue was up 7.8% compared to the same quarter last year. Equities analysts predict that DaVita Inc. will post 9.23 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on DVA shares. Truist Financial raised their price target on shares of DaVita from $130.00 to $135.00 and gave the stock a "hold" rating in a report on Tuesday, February 20th. Barclays began coverage on DaVita in a research report on Wednesday, March 6th. They set an "equal weight" rating and a $133.00 price target for the company. UBS Group lifted their price objective on DaVita from $113.00 to $134.00 and gave the stock a "buy" rating in a research report on Wednesday, February 14th. StockNews.com upgraded DaVita from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 25th. Finally, TheStreet upgraded shares of DaVita from a "c+" rating to a "b-" rating in a report on Wednesday, February 7th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, DaVita currently has an average rating of "Moderate Buy" and a consensus target price of $118.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.